Search Patents
  • Coronavirus vaccine
    Patent number: 11471525
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: October 18, 2022
    Assignee: CureVac AG
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • METHODS OF AMELIORATING AND/OR PREVENTING CORONAVIRUS-RELATED INFECTIONS
    Publication number: 20230060588
    Abstract: The invention provides a method of ameliorating and/or preventing a coronavirus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a sugar or a derivative thereof. The invention also provides a method of ameliorating and/or preventing a coronavirus infection in a subject, the method comprising upregulating sialylation of a glycan, downregulating N-glycosylation, and/or downregulating O-glycosylation of a virus particle of the coronavirus.
    Type: Application
    Filed: August 30, 2022
    Publication date: March 2, 2023
    Applicant: Glycure LLC
    Inventors: Xi CHEN, Jian ZHANG
  • Coronavirus vaccine
    Patent number: 11964011
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: April 23, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • CORONAVIRUS REPLICONS FOR ANTIVIRAL SCREENING AND TESTING
    Publication number: 20230357870
    Abstract: This application provides materials and methods related to replication competent, noninfectious coronavirus reporter replicons, such as for SARS-CoV-2, MERS, or SARS-CoV-1 comprising at least one coronavirus gene and at least one reporter gene. The application also provides methods for assaying candidate agents for inhibition of coronavirus viral replication.
    Type: Application
    Filed: September 23, 2021
    Publication date: November 9, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Xi HE, Shuo QUAN, Dai WANG, Min XU
  • METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20210393564
    Abstract: Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 23, 2021
    Inventors: Ralph A. Tripp, Jackelyn Murray, Robert Jeff Hogan
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS DISEASE-19
    Publication number: 20220257567
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating coronavirus disease 2019, and more specifically to a pharmaceutical composition for preventing or treating coronavirus disease 2019 found by drug repositioning technology using drug virtual screening technology. The pharmaceutical composition for preventing or treating coronavirus disease 2019 according to the present invention is a composition obtained by finding new uses for drugs, which have already been proven effective, for preventing or treating coronavirus disease 2019 by drug repositioning technology. The pharmaceutical composition is useful because it has significantly lower side effects than new drugs and can be rapidly applied to clinical practice.
    Type: Application
    Filed: April 27, 2021
    Publication date: August 18, 2022
    Inventors: Sang Yup LEE, Woo Dae JANG, Seungtaek KIM, Sangeun JEON
  • Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
    Patent number: 11369592
    Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: June 28, 2022
    Assignee: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Eric Holmes, Gary Ostrander, Geoffrey Stuart Dow
  • CORONAVIRUS NANOBODIES AND METHODS FOR THEIR USE AND IDENTIFICATION
    Publication number: 20240043505
    Abstract: Disclosed herein are coronavirus neutralizing antibodies and uses thereof for treating and preventing a coronavirus infection in a subject.
    Type: Application
    Filed: August 19, 2021
    Publication date: February 8, 2024
    Inventors: Yi SHI, I, Yufei XIANG
  • USE OF CATIONIC STEROIDAL ANTIMICROBIAL COMPOUNDS TO DEACTIVATE CORONAVIRUS
    Publication number: 20210379091
    Abstract: The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition to a subject, and the deactivation composition deactivating coronavirus virions in the subject or coming into contact with the subject. The method can thereby prevent, decrease, or inhibit a coronavirus infection, such as COVID-19, of the subject.
    Type: Application
    Filed: June 7, 2021
    Publication date: December 9, 2021
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Michael C. Moore
  • Methods, Compositions, and Systems for Modulation of Coronavirus Infection
    Publication number: 20240011992
    Abstract: The present disclosure relates to methods, compositions and systems for modulation of a coronavirus (e.g., SARS CoV-2) and/or the evaluation of compounds that can modulate infectivity of the coronavirus. For example, disclosed is a method to identify a compound that can modulate infection by the coronavirus comprising the steps of: expressing an angiotensin-converting enzyme 2 receptor (ACE-2) and/or a nicotinic acetylcholine receptor (nAChR) receptor on a target cell; contacting the target cell with a viral particle comprising at least a portion of the coronavirus spike protein in the absence and the presence of the compound; and measuring levels of infection of the target cell in order to determine infectivity of the viral particle in the presence or absence of the compound. Also, disclosed are compounds and methods of treatment identified using the methods, compositions, and systems.
    Type: Application
    Filed: November 11, 2021
    Publication date: January 11, 2024
    Inventors: Christos J. Petropoulos, Danielle Ditirro, Mary T. Wrin
  • Coronavirus iRNA compositions and methods of use thereof
    Patent number: 11208660
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: December 28, 2021
    Assignees: Alnylam Pharmaceuticals, Inc., Vir Biotechnology, Inc.
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
  • Compositions and methods for detecting severe acute respiratory syndrome coronavirus
    Patent number: 7129042
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: October 31, 2006
    Assignees: Diagnostic Hybrids, Inc., Health Research Incorporated
    Inventors: Laura Gillim-Ross, Jill Taylor, David R. Scholl, David E. Wentworth, Joseph D. Jollick
  • METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS
    Publication number: 20160238601
    Abstract: The present invention provides methods and compositions for detecting a coronavirus in a sample and identifying the subgroup of the coronavirus in the sample.
    Type: Application
    Filed: October 14, 2014
    Publication date: August 18, 2016
    Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount
  • COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION AND SARS
    Publication number: 20090068142
    Abstract: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection.
    Type: Application
    Filed: July 29, 2008
    Publication date: March 12, 2009
    Applicant: Three Rivers Pharmaceuticals LLC
    Inventor: Lawrence M. BLATT
  • COMPOUNDS FOR TREATING CORONAVIRUS INFECTION
    Publication number: 20240130983
    Abstract: Described herein are compounds of Formula I: wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.
    Type: Application
    Filed: December 22, 2023
    Publication date: April 25, 2024
    Applicant: NLC Pharma Ltd
    Inventor: Dorit ARAD
  • METHOD FOR INHIBITING CORONAVIRUS AND METHOD FOR TREATING DISEASE ASSOCIATED WITH CORONAVIRUS INFECTION
    Publication number: 20220072036
    Abstract: Disclosed herein is a method for inhibiting a coronavirus, which includes administering to a subject in need thereof a retinoic acid and at least one bivalent metal ion. Also disclosed is a method for treating a disease associated with coronavirus infection, which includes administering to a subject in need thereof a retinoic acid and at least one bivalent metal ion.
    Type: Application
    Filed: September 7, 2021
    Publication date: March 10, 2022
    Inventors: Bo-Lin LIN, Chung-Hsiang LIN
  • BINDING MOLECULE HAVING NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2
    Publication number: 20230113734
    Abstract: The present invention relates to a binding molecule that binds to SARS-coronavirus-2 (SARS-CoV-2). More particularly, the binding molecule of the present invention has strong ability to bind to a spike protein (S protein) on the surface of SARS-coronavirus-2 and high neutralizing activity against SARS-coronavirus-2 and is thus very useful in the diagnosis, prevention or treatment of SARS-coronavirus infection (COVID-19).
    Type: Application
    Filed: March 22, 2021
    Publication date: April 13, 2023
    Inventors: Cheol-Min KIM, Ji-Min SEO, Min-Soo KIM, Soo-Young LEE, Dong-Kyun RYU, Sung-Soon KIM, Joo-Yeon LEE, Kyung-Chang KIM, Jeong-Sun YANG, Han-Saem LEE, Hye-Min WOO, Jun-Won KIM
  • NOVEL CORONAVIRUS DUPLEX DETECTION KIT
    Publication number: 20210404023
    Abstract: The present invention provides a novel coronavirus duplex detection kit. Specifically, the present invention discloses a kit and method for multiplex detection of novel coronavirus 2019-nCoV nucleic acid, which can simultaneously detect two nucleic acid targets of the novel coronavirus 2019-nCoV and possess extremely high sensitivity and specificity, and significantly improve the accuracy of virus identification.
    Type: Application
    Filed: April 10, 2010
    Publication date: December 30, 2021
    Inventors: Xiwen JIANG, Jian FAN, Hailong PENG, Rongyu PENG
  • Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and uses thereof
    Publication number: 20060123499
    Abstract: The present invention is directed towards the use of the masked palm civet Paguma larvata (“civet”) as an animal model system for SARS, and is based on the novel demonstration of the present invention that civets may be infected with exogenous coronavirus, and that such infection produces SARS-like symptoms in these infected animals. The present invention is directed to a civet model system for the study of the infection, replication, and clinical effects of exogenously introduced human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof, and to the development of vaccines (or other methods of prevention) or treatment of infection or transmission to other civets or humans of these human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof.
    Type: Application
    Filed: December 6, 2004
    Publication date: June 8, 2006
    Inventors: Donglai Wu, Xiangang Kong, Qingwen Meng, Yonggang Liu, Yuntao Guan, Xunnan Yin, Mouping Wang, Changwen Li, Ming Liao, Chao-an Xin, Jinding Chen, Changchun Tu, Hua Xuan, Yedong Yu
  • 3CLPRO-TARGETING PHILLYRIN, DERIVATIVE THEREOF, AND USE THEREOF AGAINST NOVEL CORONAVIRUS
    Publication number: 20230101803
    Abstract: The present invention provides a use of a phillyrin/phillygenin composition which targets and inhibits 3CLpro protein of COVID-19 virus, in preparation of an anti-coronavirus drug or a drug for treating a disease caused by the coronavirus, wherein the coronavirus is COVID-19 virus, and the disease caused by the coronavirus is COVID-19.
    Type: Application
    Filed: February 9, 2021
    Publication date: March 30, 2023
    Inventors: Zifeng YANG, Li FU, Ge JIANG, Nanshan ZHONG, Wei YANG, Qinhai MA, Min HUI, Chufang LI, Shuo WANG, Weiyi PAN, Qi LU, Aiai SONG, Jirui HOU, Runfeng LI, Mingming LU, Yingping WANG, Yang LIU, Guoyou LIU, Wenfei FU, Xue FENG, Qingfeng ZHOU, Xiaofeng YI, Rongxin LIN, Yu ZHANG
Narrow Results

Filter by US Classification